Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

Overactive Bladder Clinical Trial

— OAB  

Official title:

Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01870037
• Other study ID #: ION 03-OAB
• Status: Completed
• Phase: Phase 1
• Start date: January 2013
• Est. completion date: February 17, 2018

Study information

• Verified date: May 2019
• Source: Urovant Sciences GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections. Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive placebo.

Description:

This is a Phase 1 double-blind, placebo-controlled study assessing the safety and activity of 2 escalating doses of hMaxi-K gene transfer by direct injection into the bladder wall in female participants with OAB/DO.

The safety parameters to be monitored include: adverse events, clinical laboratory tests, electrocardiograms, and physical examinations.

The secondary objective is to evaluate the efficacy of multiple intramuscular injections of hMaxi-K compared to the control group. Efficacy parameters that will be evaluated are: number of micturitions per 24 hours, volume per micturition, incontinence episodes, pad weight measurement of accidental bladder leaks, uninhibited contractions during cystoscopy and other cystoscopic evaluations, and general and bladder-specific quality of life assessments (Kings Health Questionnaire, SF-12 Health Survey, and International Consultation on Incontinence Questionnaire [ICIQ-SF]).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: February 17, 2018
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Healthy women of =18 years of age and non-childbearing potential

2. Symptoms of overactive bladder for =6 months including at least one of the following:

1. Frequent micturition =8 times per 24 hours

2. Urinary urgency or nocturia

3. Urge urinary incontinence five or more incontinence episodes per week

3. Detrusor overactivity with =1 uncontrolled phasic contraction(s) of the detrusor of at least 5 centimeters/H20 pressure documented on cystometry at Screening Visit 1A

4. Residual urine volume of =200 milliliters (ml)

5. Non-response or poor tolerance to previous treatment for symptoms of OAB/urinary incontinence and do not wish to continue these treatments

6. Have screening laboratory values and electrocardiogram that are within the normal range

7. Able to understand study requirements (i.e., literate in English), give written informed consent, and comply with all study procedures and requirements.

Exclusion Criteria:

• A woman with a positive serum (HCG) pregnancy test or who is lactating

• History of three or more culture-documented recurrent urinary tract infections per year

• Current history or previous diagnosis of painful bladder syndrome (interstitial cystitis) with pain in the region of the pelvis, perineum, or lower abdomen relieved by voiding

• Current history of neurological bladder dysfunction

• A life expectancy of less than 12 months

• Current history of Grade 2 or greater cystocele

• An indwelling urethral catheter or need for clean intermittent self-catheterization

• Recent heart attack

• Uncontrolled diabetes

• Latex allergy

• Stress urinary incontinence as determined by observation of the participant coughing while standing with a full bladder and/or response of 2 or 3 on the following Stress Urinary Incontinence question: Do you experience leakage when laughing, coughing, lifting heavy objects or other types of discreet, moderately intense activities? 0=NONE: No leakage. 1=MILD: Minimal leakage on rare occasions during these types of activities; easily tolerated; do not use pads for this. 2=MODERATE: Enough leakage that it requires occasional use of pads and may interfere with usual activity and tasks. 3=SEVERE: Extreme leakage and discomfort that stops all activity and tasks and requires the use of pads on all occasions

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Drug:
• Placebo (PBS-20% sucrose)

• hMaxi-K
Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)

Locations

Country	Name	City	State
United States	AccuMed Research Associates	Garden City	New York
United States	NYU	New York	New York
United States	Premier Medical Group of the Hudson Valley, PC	Poughkeepsie	New York

Sponsors (2)

Lead Sponsor	Collaborator
Urovant Sciences GmbH	Ion Channel Innovations

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with any treatment-emergent adverse event during the Treatment Period		6 months (24 weeks) per participant
Primary	Number of participants with any treatment-emergent adverse event during the Safety Follow-up Period		18 months
Primary	Number of participants with any clinically significant clinical laboratory test value during the Treatment Period		6 months (24 weeks) per participant
Primary	Number of participants with any clinically significant clinical laboratory test value during the Safety Follow-up Period		18 months
Primary	Number of participants with any clinically significant electrocardiogram finding during the Treatment Period		6 months (24 weeks) per participant
Primary	Number of participants with any clinically significant electrocardiogram finding during the Safety Follow-up Period		18 months
Primary	Number of participants with any clinically significant physical examination finding during the Treatment Period		6 months (24 weeks) per participant
Primary	Number of participants with any clinically significant physical examination finding during the Safety Follow-up Period		18 months
Secondary	Change from Baseline in the number of micturitions per day		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in the volume of micturitions		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in incontinence episodes		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in pad weight		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in uninhibited contractions during cystoscopy		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in the participant rating of the Kings Health Questionnaire (KHQ) score		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in the International Consultation on Incontinence Questionnaire-Short Form score		Baseline; 6 months (24 weeks) per participant
Secondary	Change from Baseline in the Short Form-12 (SF-12) score		Baseline; 6 months (24 weeks) per participant